RDY
Price
$15.09
Change
-$0.24 (-1.57%)
Updated
Jun 27, 01:18 PM (EDT)
Capitalization
12.48B
26 days until earnings call
ZTS
Price
$156.26
Change
+$0.47 (+0.30%)
Updated
Jun 27, 02:04 PM (EDT)
Capitalization
77.48B
46 days until earnings call
Interact to see
Advertisement

RDY vs ZTS

Header iconRDY vs ZTS Comparison
Open Charts RDY vs ZTSBanner chart's image
Dr. Reddy's Laboratories
Price$15.09
Change-$0.24 (-1.57%)
Volume$1.73K
Capitalization12.48B
ZOETIS
Price$156.26
Change+$0.47 (+0.30%)
Volume$801
Capitalization77.48B
RDY vs ZTS Comparison Chart in %
Loading...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RDY vs. ZTS commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RDY is a Hold and ZTS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (RDY: $15.33 vs. ZTS: $155.79)
Brand notoriety: RDY: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: RDY: 86% vs. ZTS: 104%
Market capitalization -- RDY: $12.48B vs. ZTS: $77.48B
RDY [@Pharmaceuticals: Other] is valued at $12.48B. ZTS’s [@Pharmaceuticals: Other] market capitalization is $77.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RDY’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • RDY’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, RDY is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RDY’s TA Score shows that 4 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).

  • RDY’s TA Score: 4 bullish, 5 bearish.
  • ZTS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than RDY.

Price Growth

RDY (@Pharmaceuticals: Other) experienced а +0.92% price change this week, while ZTS (@Pharmaceuticals: Other) price change was +0.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +114.11%. For the same industry, the average monthly price growth was +75.08%, and the average quarterly price growth was +82.00%.

Reported Earning Dates

RDY is expected to report earnings on Jul 23, 2025.

ZTS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+114.11% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($77.5B) has a higher market cap than RDY($12.5B). ZTS has higher P/E ratio than RDY: ZTS (32.94) vs RDY (19.68). RDY YTD gains are higher at: -2.913 vs. ZTS (-3.770). RDY has higher annual earnings (EBITDA): 84.9B vs. ZTS (3.67B). RDY has more cash in the bank: 72.4B vs. ZTS (2.04B). ZTS has less debt than RDY: ZTS (6.76B) vs RDY (19.9B). RDY has higher revenues than ZTS: RDY (271B) vs ZTS (8.54B).
RDYZTSRDY / ZTS
Capitalization12.5B77.5B16%
EBITDA84.9B3.67B2,316%
Gain YTD-2.913-3.77077%
P/E Ratio19.6832.9460%
Revenue271B8.54B3,172%
Total Cash72.4B2.04B3,551%
Total Debt19.9B6.76B295%
FUNDAMENTALS RATINGS
RDY vs ZTS: Fundamental Ratings
RDY
ZTS
OUTLOOK RATING
1..100
7978
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
3180
SMR RATING
1..100
4819
PRICE GROWTH RATING
1..100
4660
P/E GROWTH RATING
1..100
4370
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZTS's Valuation (65) in the Pharmaceuticals Generic industry is in the same range as RDY (79). This means that ZTS’s stock grew similarly to RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (31) in the Pharmaceuticals Generic industry is somewhat better than the same rating for ZTS (80). This means that RDY’s stock grew somewhat faster than ZTS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is in the same range as RDY (48). This means that ZTS’s stock grew similarly to RDY’s over the last 12 months.

RDY's Price Growth Rating (46) in the Pharmaceuticals Generic industry is in the same range as ZTS (60). This means that RDY’s stock grew similarly to ZTS’s over the last 12 months.

RDY's P/E Growth Rating (43) in the Pharmaceuticals Generic industry is in the same range as ZTS (70). This means that RDY’s stock grew similarly to ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RDYZTS
RSI
ODDS (%)
Bearish Trend 2 days ago
62%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
46%
Bearish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 5 days ago
52%
Bullish Trend 5 days ago
59%
Declines
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 2 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
50%
Bullish Trend 2 days ago
62%
Aroon
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVVE0.940.03
+3.73%
Nuvve Holding Corp
TBPH10.730.15
+1.42%
Theravance Biopharma
FCPT27.300.36
+1.34%
Four Corners Property Trust
COTY4.60-0.04
-0.86%
COTY
TOP1.23-0.05
-4.28%
TOP Financial Group Limited

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
-1.10%
COLL - RDY
31%
Poorly correlated
+0.37%
KMDA - RDY
30%
Poorly correlated
+0.51%
ZTS - RDY
27%
Poorly correlated
-0.92%
AMPH - RDY
27%
Poorly correlated
-1.15%
OGI - RDY
26%
Poorly correlated
+2.94%
More